SG Americas Securities LLC lessened its holdings in shares of Metlife Inc (NYSE:MET) by 34.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 124,997 shares of the financial services provider’s stock after selling 66,960 shares during the quarter. SG Americas Securities LLC’s holdings in Metlife were worth $5,895,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in MET. Nuveen Asset Management LLC lifted its holdings in shares of Metlife by 784.3% in the second quarter. Nuveen Asset Management LLC now owns 5,545,597 shares of the financial services provider’s stock valued at $275,449,000 after buying an additional 4,918,508 shares during the period. AQR Capital Management LLC raised its position in shares of Metlife by 32.0% during the second quarter. AQR Capital Management LLC now owns 6,133,536 shares of the financial services provider’s stock worth $304,653,000 after purchasing an additional 1,488,231 shares during the period. BlackRock Inc. raised its position in shares of Metlife by 1.9% during the second quarter. BlackRock Inc. now owns 72,819,515 shares of the financial services provider’s stock worth $3,616,945,000 after purchasing an additional 1,385,433 shares during the period. Panagora Asset Management Inc. raised its position in shares of Metlife by 114.8% during the second quarter. Panagora Asset Management Inc. now owns 2,286,663 shares of the financial services provider’s stock worth $113,579,000 after purchasing an additional 1,222,194 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Metlife by 18.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 5,986,416 shares of the financial services provider’s stock worth $297,346,000 after purchasing an additional 933,688 shares during the period. Institutional investors own 75.59% of the company’s stock.
NYSE:MET traded up $0.28 during trading hours on Friday, hitting $49.32. 5,509,790 shares of the company’s stock traded hands, compared to its average volume of 5,417,675. The firm has a market cap of $45.78 billion, a P/E ratio of 9.15, a P/E/G ratio of 1.09 and a beta of 1.12. Metlife Inc has a twelve month low of $37.76 and a twelve month high of $51.16. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.14 and a current ratio of 0.15. The stock’s fifty day moving average price is $46.53 and its two-hundred day moving average price is $47.39.
Metlife (NYSE:MET) last posted its quarterly earnings results on Wednesday, October 30th. The financial services provider reported $1.27 earnings per share for the quarter, missing the consensus estimate of $1.40 by ($0.13). The business had revenue of $16.92 billion for the quarter, compared to analyst estimates of $16.37 billion. Metlife had a net margin of 10.82% and a return on equity of 8.82%. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.38 earnings per share. On average, equities research analysts predict that Metlife Inc will post 5.55 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Tuesday, November 5th will be paid a $0.44 dividend. The ex-dividend date is Monday, November 4th. This represents a $1.76 dividend on an annualized basis and a yield of 3.57%. Metlife’s dividend payout ratio (DPR) is currently 32.65%.
MET has been the topic of a number of recent analyst reports. Citigroup cut their target price on Metlife from $42.00 to $41.00 and set a “sell” rating on the stock in a research report on Friday, September 13th. UBS Group upped their price target on Metlife from $46.00 to $47.00 and gave the company a “neutral” rating in a research report on Thursday, October 10th. Morgan Stanley dropped their price target on Metlife from $54.00 to $53.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 20th. ValuEngine raised Metlife from a “strong sell” rating to a “sell” rating in a research report on Monday, November 4th. Finally, B. Riley reissued a “neutral” rating on shares of Metlife in a research report on Tuesday, October 15th. Three analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company’s stock. Metlife has a consensus rating of “Hold” and an average price target of $49.51.
Metlife Company Profile
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
See Also: What is Blockchain?
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metlife Inc (NYSE:MET).
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.